Bogdan Mitran

Publications
Public outreach and news

Articles

Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;21(6):E1972-1972
Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(12):3347-3358
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Article: SCIENTIFIC REPORTS. 2019;9(1):17710
Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: SCIENTIFIC REPORTS. 2019;9(1):17086
Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
Mitran B; Thisgaard H; Rinne S; Dam JH; Azami F; Tolmachev V; Orlova A; Rosenström U
Article: SCIENTIFIC REPORTS. 2019;9(1):14907
Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
Article: CANCERS. 2019;11(9):E1371-1371
Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
Mitran B; Varasteh Z; Abouzayed A; Rinne SS; Puuvuori E; De Rosa M; Larhed M; Tolmachev V; Orlova A; Rosenstrom U
Article: PHARMACEUTICS. 2019;11(8):E380-380
Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.
Oroujeni M; Abouzayed A; Lundmark F; Mitran B; Orlova A; Tolmachev V; Rosenström U
Article: PHARMACEUTICS. 2019;11(7):E358-358
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
Abouzayed A; Yim C-B; Mitran B; Rinne SS; Tolmachev V; Larhed M; Rosenström U; Orlova A
Article: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2019;140:109-120
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.
von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
Article: BIOMATERIALS. 2019;203:73-85
Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.
Westerlund K; Vorobyeva A; Mitran B; Orlova A; Tolmachev V; Karlström AE; Altai M
Article: SCIENTIFIC REPORTS. 2019;9(1):6779
Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2019;54(4):1209-1220
Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Article: MOLECULAR PHARMACEUTICS. 2019;16(3):995-1008
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2019;20(5):E1080-1080
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: SCIENTIFIC REPORTS. 2019;9(1):655
Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: ONCOLOGY REPORTS. 2019;41(1):534-542
Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.
Mitran B; Andersson KG; Lindström E; Garousi J; Rosestedt M; Tolmachev V; Ståhl S; Orlova A; Löfblom J
Article: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2019;134:37-48
Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
Article: JOURNAL OF CONTROLLED RELEASE. 2018;288:84-95
Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist P-H; Tolmachev V; Orlova A; Gräslund T
Article: CELLS. 2018;7(9):E141-141
Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.
Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
Article: AMINO ACIDS. 2018;50(8):981-994
Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.
Oroujeni M; Andersson KG; Steinhardt X; Altai M; Orlova A; Mitran B; Vorobyeva A; Garousi J; Tolmachev V; Löfblom J
Article: MOLECULAR PHARMACEUTICS. 2018;15(7):2674-2683
Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga.
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Article: JOURNAL OF NUCLEAR MEDICINE. 2018;59(7):1092-1098
Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle.
Westerlund K; Altai M; Mitran B; Konijnenberg M; Oroujeni M; Atterby C; de Jong M; Orlova A; Mattsson J; Micke P; Karlström AE; Tolmachev V
Article: SCIENTIFIC REPORTS. 2018;8(1):9643
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.
Vorobyeva A; Westerlund K; Mitran B; Altai M; Rinne S; Sörensen J; Orlova A; Tolmachev V; Karlström AE
Article: CONTRAST MEDIA & MOLECULAR IMAGING. 2018;2018:6930425-11
Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Article: MOLECULAR PHARMACEUTICS. 2018;15(1):175-185
Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Article: JOURNAL OF NUCLEAR MEDICINE. 2018;59(1):93-99
Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
Article: THERANOSTICS. 2018;8(16):4462-4476
Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Mitran B; Güler R; Roche FP; Lindström E; Selvaraju RK; Fleetwood F; Rinne SS; Claesson-Welsh L; Tolmachev V; Ståhl S; Orlova A; Löfblom J
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2017;51(6):1765-1774
Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Article: SCIENTIFIC REPORTS. 2017;7(1):14780
Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.
Garousi J; Lindbo S; Mitran B; Buijs J; Vorobyeva A; Orlova A; Tolmachev V; Hober S
Article: NUCLEAR MEDICINE AND BIOLOGY. 2017;54:1-9
Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and 177Lu labeling.
Altai M; Westerlund K; Velletta J; Mitran B; Honarvar H; Karlström AE
Article: SCIENTIFIC REPORTS. 2017;7(1):5961
The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.
Garousi J; Andersson KG; Dam JH; Olsen BB; Mitran B; Orlova A; Buijs J; Ståhl S; Löfblom J; Thisgaard H; Tolmachev V
Article: SCIENTIFIC REPORTS. 2017;7:43118
In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.
Bass TZ; Rosestedt M; Mitran B; Frejd FY; Löfblom J; Tolmachev V; Ståhl S; Orlova A
Article: CONTRAST MEDIA & MOLECULAR IMAGING. 2017;2017:6873684-10
High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.
Mitran B; Thisgaard H; Rosenström U; Dam JH; Larhed M; Tolmachev V; Orlova A
Article: CHEMISTRYOPEN. 2016;5(6):566-573
Synthesis of 11C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [11C]CO.
Stevens MY; Chow SY; Estrada S; Eriksson J; Asplund V; Orlova A; Mitran B; Antoni G; Larhed M; Åberg O; Odell LR
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2016;49(6):2285-2293
Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.
Andersson KG; Oroujeni M; Garousi J; Mitran B; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Article: BIOCONJUGATE CHEMISTRY. 2016;27(11):2678-2688
Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.
Garousi J; Lindbo S; Honarvar H; Velletta J; Mitran B; Altai M; Orlova A; Tolmachev V; Hober S
Article: MOLECULAR PHARMACEUTICS. 2016;13(11):3676-3687
Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.
Garousi J; Honarvar H; Andersson KG; Mitran B; Orlova A; Buijs J; Löfblom J; Frejd FY; Tolmachev V
Article: MOLECULAR PHARMACEUTICS. 2016;13(5):1668-1678
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2016;48(5):2124-2134
Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2016;48(4):1325-1332
PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl M-L; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Article: JOURNAL OF NUCLEAR MEDICINE. 2016;57(3):431-436
Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
Article: SCIENTIFIC REPORTS. 2015;5:15226
Affibody-mediated PET imaging of HER3 expression in malignant tumours.
Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(5):446-454
The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Article: AMINO ACIDS. 2015;47(2):303-315
Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
Article: MOLECULES. 2014;19(7):10455-10472
The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.
Varasteh Z; Rosenström U; Velikyan I; Mitran B; Altai M; Honarvar H; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Show more

All other publications

Review: CURRENT MEDICINAL CHEMISTRY. 2020;27(41):7090-7111
Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties.
Mitran B; Tolmachev V; Orlova A

Articles

All other publications

News from KI

Events from KI